Miguel Araújo Abreu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Miguel Araújo Abreu has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
Ricardo Sousa
Department of Orthopaedic Surgery, Centro Hospitalar e Universitário de Santo António, Porto, Portugal
6 shared publications- Ricardo Sousa
Orthopaedic Department, Unidade Local de Saúde Santo António, Porto, Portugal
5 shared publications - Ana Cipriano
Department of Infectious Diseases of Porto Hospital Center
3 shared publications Daniel Soares
Department of Orthopaedics, Centro Hospitalar Universitário do Porto, Porto, Portugal
3 shared publications- Fábio Videira Santos
Doenças Infeciosas. Departamento de Medicina. Instituto Português de Oncologia do Porto. Porto
3 shared publications - Inês Alves
Institute for Research and Innovation in Health (i3s), University of Porto, 4200-135 Porto, Portugal
3 shared publications
Latest Publications
- Open Access
- 24 March 2026
- Published by Sociedade Portuguesa de Doenças Infecciosas e Microbiologia Clínica in Revista Portuguesa de Doenças Infecciosas (RPDI)
- Vol. 20 (1) , 33-48
Balancing Scalpel and Antibiotics: A Modern Approach to Bone and Joint Infection Management
Background: Bone and joint infections are challenging musculoskeletal conditions, often associated with high morbidity and functional impairment. Implant-associated infections are particularly difficult to treat due to biofilm-mediated bacterial resistance. Objective: To provide an interdisciplinary algorithm for the management of bone and joint infections, including guidance on implant retention or removal. Context: Current evidence on septic arthritis, osteomyelitis, fracture-related infections, and prosthetic joint infections was reviewed. Core management principles include radical debridement, microbiological sampling, stabilization, soft tissue coverage, and tailored antibiotic therapy. Treatment strategies depend on implant presence and infection chronicity, including debridement, antibiotics, and implant retention (DAIR), staged revision, or suppressive antibiotic therapy. Key concepts: Implant-free infections are treated with extensive debridement and six weeks of antibiotic therapy. Acute implant-associated infections may be managed with DAIR combined with anti-biofilm antibiotics, achieving cure rates of 60.0 – 90.0% under optimal conditions. Chronic infections or mature biofilm typically require staged implant removal and reconstruction. While single-stage revision is feasible in selected cases, two-stage procedures remain standard for complex infections. Antimicrobial duration should be individualized according to clinical response. Conclusions: Successful management relies on a multidisciplinary approach integrating surgical and medical strategies. Individualized therapy based on implant status, biofilm presence, and patient-specific factors is essential to maximize infection eradication and functional recovery.
- 24 March 2026
- Published by Sociedade Portuguesa de Doenças Infecciosas e Microbiologia Clínica in Revista Portuguesa de Doenças Infecciosas (RPDI)
- Vol. 20 (1) , 33-48
Open AccessBalancing Scalpel and Antibiotics: A Modern Approach to Bone and Joint Infection Management
Background: Bone and joint infections are challenging musculoskeletal conditions, often associated with high morbidity and functional impairment. Implant-associated infections are particularly difficult to treat due to biofilm-mediated bacterial resistance. Objective: To provide an interdisciplinary algorithm for the management of bone and joint infections, including guidance on implant retention or removal. Context: Current evidence on septic arthritis, osteomyelitis, fracture-related infections, and prosthetic joint infections was reviewed. Core management principles include radical debridement, microbiological sampling, stabilization, soft tissue coverage, and tailored antibiotic therapy. Treatment strategies depend on implant presence and infection chronicity, including debridement, antibiotics, and implant retention (DAIR), staged revision, or suppressive antibiotic therapy. Key concepts: Implant-free infections are treated with extensive debridement and six weeks of antibiotic therapy. Acute implant-associated infections may be managed with DAIR combined with anti-biofilm antibiotics, achieving cure rates of 60.0 – 90.0% under optimal conditions. Chronic infections or mature biofilm typically require staged implant removal and reconstruction. While single-stage revision is feasible in selected cases, two-stage procedures remain standard for complex infections. Antimicrobial duration should be individualized according to clinical response. Conclusions: Successful management relies on a multidisciplinary approach integrating surgical and medical strategies. Individualized therapy based on implant status, biofilm presence, and patient-specific factors is essential to maximize infection eradication and functional recovery.
- Open Access
- 24 September 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (10) , 2241
The Impact of Antibiotic Therapy Options and Multidisciplinary Approach in Prosthetic Joint Infections
Periprosthetic joint infection (PJI) remains one of the most challenging complications of arthroplasty. Optimal antibiotic strategies and the role of multidisciplinary teams (MDT) are not fully defined. We retrospectively analyzed 86 PJI surgical procedures performed between 2017 and 2023 at a tertiary referral center. Clinical data, microbiology, surgical strategy (debridement, antibiotics, and implant retention -DAIR, one-stage, two-stage) and antibiotic regimens were collected. Outcomes were compared across antibiotic classes and treatment teams: orthopaedics alone, orthopaedics with MDT input, and a dedicated MDT (GRIP). Success was defined as infection-free survival without further surgery. Median patient age was 70 years, with high comorbidity and predominance of Gram-positive, monomicrobial infections. Rifampicin-based regimens were associated with higher cure rates than non-anti-biofilm therapy (OR 4.9, 95% CI 1.4–17.8). Flucloxacillin plus rifampicin achieved outcomes comparable to rifampicin–fluoroquinolone combinations. The strongest predictor of success was MDT involvement: in DAIR procedures, cure reached 100% with MDT versus 48% with orthopaedics alone (p = 0.025). Outcomes were similar between teams in one- and two-stage revisions. In this cohort, rifampicin-based therapy improved outcomes in staphylococcal PJI, and flucloxacillin was a valid alternative partner drug. Crucially, MDT management—particularly in DAIR—was associated with superior results. These findings highlight the value of structured multidisciplinary PJI care pathways alongside optimised antibiotic strategies.
- 24 September 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (10) , 2241
Open AccessThe Impact of Antibiotic Therapy Options and Multidisciplinary Approach in Prosthetic Joint Infections
Periprosthetic joint infection (PJI) remains one of the most challenging complications of arthroplasty. Optimal antibiotic strategies and the role of multidisciplinary teams (MDT) are not fully defined. We retrospectively analyzed 86 PJI surgical procedures performed between 2017 and 2023 at a tertiary referral center. Clinical data, microbiology, surgical strategy (debridement, antibiotics, and implant retention -DAIR, one-stage, two-stage) and antibiotic regimens were collected. Outcomes were compared across antibiotic classes and treatment teams: orthopaedics alone, orthopaedics with MDT input, and a dedicated MDT (GRIP). Success was defined as infection-free survival without further surgery. Median patient age was 70 years, with high comorbidity and predominance of Gram-positive, monomicrobial infections. Rifampicin-based regimens were associated with higher cure rates than non-anti-biofilm therapy (OR 4.9, 95% CI 1.4–17.8). Flucloxacillin plus rifampicin achieved outcomes comparable to rifampicin–fluoroquinolone combinations. The strongest predictor of success was MDT involvement: in DAIR procedures, cure reached 100% with MDT versus 48% with orthopaedics alone (p = 0.025). Outcomes were similar between teams in one- and two-stage revisions. In this cohort, rifampicin-based therapy improved outcomes in staphylococcal PJI, and flucloxacillin was a valid alternative partner drug. Crucially, MDT management—particularly in DAIR—was associated with superior results. These findings highlight the value of structured multidisciplinary PJI care pathways alongside optimised antibiotic strategies.
- Open Access
- 29 August 2024
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 15, 1435720
Antibiotics with antibiofilm activity – rifampicin and beyond
The management of prosthetic joint infections is a complex and multilayered process that is additionally complicated by the formation of bacterial biofilm. Foreign material provides the ideal grounds for the development of an intricate matrix that hinders treatment and creates a difficult environment for antibiotics to act. Surgical intervention is often warranted but requires appropriate adjunctive therapy. Despite available guidelines, several aspects of antibiotic therapy with antibiofilm activity lack clear definition. Given the escalating challenges posed by antimicrobial resistance, extended treatment durations, and tolerance issues, it is essential to ensure that antimicrobials with antibiofilm activity are both potent and diverse. Evidence of biofilm-active drugs is highlighted, and alternatives to classical regimens are further discussed.
- 29 August 2024
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 15, 1435720
Open AccessAntibiotics with antibiofilm activity – rifampicin and beyond
The management of prosthetic joint infections is a complex and multilayered process that is additionally complicated by the formation of bacterial biofilm. Foreign material provides the ideal grounds for the development of an intricate matrix that hinders treatment and creates a difficult environment for antibiotics to act. Surgical intervention is often warranted but requires appropriate adjunctive therapy. Despite available guidelines, several aspects of antibiotic therapy with antibiofilm activity lack clear definition. Given the escalating challenges posed by antimicrobial resistance, extended treatment durations, and tolerance issues, it is essential to ensure that antimicrobials with antibiofilm activity are both potent and diverse. Evidence of biofilm-active drugs is highlighted, and alternatives to classical regimens are further discussed.
- Open Access
- 29 March 2023
- Published by Copernicus GmbH in Journal of Bone and Joint Infection
- Vol. 8 (2) , 109-118
Simple and inexpensive synovial fluid biomarkers for the diagnosis of prosthetic joint infection according to the new EBJIS definition
Introduction: diagnosis of periprosthetic joint infection (PJI) is challenging, as no single test has absolute accuracy. The purpose of this study was to assess the utility of different simple synovial biomarkers in the diagnosis of PJI as defined by the European Bone and Joint Infection Society (EBJIS). Methods: we retrospectively identified all patients undergoing revision hip or knee arthroplasty from 2013 to 2019 on our prospectively maintained database. Only patients with minimum required infection diagnostic workup were included in the study. Patients with comorbidities that may influence the accuracy of synovial biomarkers were excluded. Receiver operator characteristic (ROC) curves were utilised to assess the diagnostic utility of synovial fluid white blood cell (WBC) count, polymorphonuclear leukocyte percentage (PMN %), C-reactive protein (CRP), adenosine deaminase (ADA), and alpha-2-microglobulin (A2M). Results: in total, 102 patients met the inclusion criteria. Of these, 58 were classified as infection unlikely, 8 as infection likely, and 36 as infection confirmed. Synovial WBC count (area under the curve (AUC) 0.94) demonstrated the best utility for the diagnosis of PJI, followed by PMN % (AUC 0.91), synovial CRP (AUC 0.90), ADA (AUC 0.82), and A2M (AUC 0.76). We found added value in the combined interpretation of different biomarkers. We calculated high sensitivity and negative predictive value if at least two of them are negative and high specificity and positive predictive value if at least two are elevated. Conclusion: current results show that synovial fluid investigation is a useful tool for the diagnosis of PJI, and the combined interpretation of simple and inexpensive biomarkers demonstrated improved diagnostic accuracy.
- 29 March 2023
- Published by Copernicus GmbH in Journal of Bone and Joint Infection
- Vol. 8 (2) , 109-118
Open AccessSimple and inexpensive synovial fluid biomarkers for the diagnosis of prosthetic joint infection according to the new EBJIS definition
Introduction: diagnosis of periprosthetic joint infection (PJI) is challenging, as no single test has absolute accuracy. The purpose of this study was to assess the utility of different simple synovial biomarkers in the diagnosis of PJI as defined by the European Bone and Joint Infection Society (EBJIS). Methods: we retrospectively identified all patients undergoing revision hip or knee arthroplasty from 2013 to 2019 on our prospectively maintained database. Only patients with minimum required infection diagnostic workup were included in the study. Patients with comorbidities that may influence the accuracy of synovial biomarkers were excluded. Receiver operator characteristic (ROC) curves were utilised to assess the diagnostic utility of synovial fluid white blood cell (WBC) count, polymorphonuclear leukocyte percentage (PMN %), C-reactive protein (CRP), adenosine deaminase (ADA), and alpha-2-microglobulin (A2M). Results: in total, 102 patients met the inclusion criteria. Of these, 58 were classified as infection unlikely, 8 as infection likely, and 36 as infection confirmed. Synovial WBC count (area under the curve (AUC) 0.94) demonstrated the best utility for the diagnosis of PJI, followed by PMN % (AUC 0.91), synovial CRP (AUC 0.90), ADA (AUC 0.82), and A2M (AUC 0.76). We found added value in the combined interpretation of different biomarkers. We calculated high sensitivity and negative predictive value if at least two of them are negative and high specificity and positive predictive value if at least two are elevated. Conclusion: current results show that synovial fluid investigation is a useful tool for the diagnosis of PJI, and the combined interpretation of simple and inexpensive biomarkers demonstrated improved diagnostic accuracy.
- Top Cited PapersOpen Access
- 12 January 2023
- Published by Copernicus GmbH in Journal of Bone and Joint Infection
- Vol. 8 (1) , 29-37
Guideline for management of septic arthritis in native joints (SANJO)
This clinical guideline is intended for use by orthopedic surgeons and physicians who care for patients with possible or documented septic arthritis of a native joint (SANJO). It includes evidence and opinion-based recommendations for the diagnosis and management of patients with SANJO.
- 12 January 2023
- Published by Copernicus GmbH in Journal of Bone and Joint Infection
- Vol. 8 (1) , 29-37
Top Cited PapersOpen AccessGuideline for management of septic arthritis in native joints (SANJO)
This clinical guideline is intended for use by orthopedic surgeons and physicians who care for patients with possible or documented septic arthritis of a native joint (SANJO). It includes evidence and opinion-based recommendations for the diagnosis and management of patients with SANJO.
- Open Access
- 1 July 2022
- Published by Ordem dos Medicos in Acta Medica Portuguesa
- Vol. 35 (7-8) , 593-603
Protocolo Intra-Hospitalar para Abordagem da Doença COVID-19 no Adulto
The COVID-19 pandemic is currently responsible for over 526 million infections and over 6.3 million deaths. As a new disease, the number of papers on the subject is extensive, motivating considerable heterogeneity in its approach. Despite some medicines having sound evidence of benefit, new interventions and strategies continue to be proposed, and some still lack scientific evidence, which hinders a uniform and consensual approach. This article aims to standardize healthcare to adult patients with moderate-to-critical COVID-19, from the emergency department to hospitalization, either in a general ward or in level 2 or level 3 intensive care units, based on the best and most updated scientific evidence available. This protocol presents recommendations for the stratification of adult patients with COVID-19 disease, adequate workup at admission and during hospitalization, inpatient treatment criteria, general treatment measures, pharmacological treatment, management of complications such as organizing pneumonia and bacterial superinfection, thromboprophylaxis, special considerations on pregnancy and breastfeeding and possible future therapies.
- 1 July 2022
- Published by Ordem dos Medicos in Acta Medica Portuguesa
- Vol. 35 (7-8) , 593-603
Open AccessProtocolo Intra-Hospitalar para Abordagem da Doença COVID-19 no Adulto
The COVID-19 pandemic is currently responsible for over 526 million infections and over 6.3 million deaths. As a new disease, the number of papers on the subject is extensive, motivating considerable heterogeneity in its approach. Despite some medicines having sound evidence of benefit, new interventions and strategies continue to be proposed, and some still lack scientific evidence, which hinders a uniform and consensual approach. This article aims to standardize healthcare to adult patients with moderate-to-critical COVID-19, from the emergency department to hospitalization, either in a general ward or in level 2 or level 3 intensive care units, based on the best and most updated scientific evidence available. This protocol presents recommendations for the stratification of adult patients with COVID-19 disease, adequate workup at admission and during hospitalization, inpatient treatment criteria, general treatment measures, pharmacological treatment, management of complications such as organizing pneumonia and bacterial superinfection, thromboprophylaxis, special considerations on pregnancy and breastfeeding and possible future therapies.
- 30 June 2022
- Published by Revista Portuguesa de Saude Ocupacional in Revista Portuguesa de Saúde Ocupacional
- Vol. 13, 45-60
Vigilância da Tuberculose nos Profissionais de Saúde como contributo na erradicação de uma Pandemia
Introduction/Framework Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis. Despite the available treatment, it’s an important driver of global morbidity and mortality. It reaches mainly the lungs but can reach any organ. The main route of infection is inhalation of aerosolized particles or contaminated micro-droplets. Global efforts for early diagnosis and adequate treatment have made it possible to remove Tuberculosis from the worldwide ten leading causes of death in 2019. The worldwide incidence is around ten million, probably underestimated. Tuberculosis represents an often-overlooked pandemic, which remains an important cause of death from an infectious disease whose, in contrast to other infections, incidence has recently risen as occupational disease. Methodology It’s a narrative review of the national and international guidelines about Tuberculosis in healthcare workers, with an adaptation to the Portuguese reality using estimations from countries with a similar disease incidence. Contents The World Health Organization argues that the benefit of screening and treating Latent Tuberculosis Infection outweighs the individual risks and therefore should be performed whenever possible. Following these guidelines, the Portuguese health council (Direção-Geral da Saúde) determined that health institutions, within the scope of health surveillance of their workers, must adopt procedures that allow for the early detection of Tuberculosis and Latent Tuberculosis Infection. Thus, the Occupational Medicine Services are responsible for assessing and manage the professional exposure to this biological agent. The End TB Strategy program aspires to the worldwide eradication of Tuberculosis by 2035, aiming to reduce Tuberculosis incidence and mortality by 80 and 95%, respectively, as well as universal access to proper treatment. Discussion and Conclusions The authors argue that the institutional contribution with the reinforcement of hospital infection control measures, the implementation of regular occupational Tuberculosis surveillance programs and the containment of the disease, through timely screening after unprotected exposure, are essentials measures for the achievement of the ambitious outlined goals. Regardless of their job model, these programs should be applied to all workers, contributing to the maintenance of their health, the main Occupational Medicine’s goal. Finally, the authors share ten common questions from daily basis clinical practice and present methodological suggestions. KEY-WORDS: Labor Health Surveillance; Healthcare workers; Prevention of Occupational Diseases; Screening; Tuberculosis; Latent Tuberculosis Infection.
- 30 June 2022
- Published by Revista Portuguesa de Saude Ocupacional in Revista Portuguesa de Saúde Ocupacional
- Vol. 13, 45-60
Vigilância da Tuberculose nos Profissionais de Saúde como contributo na erradicação de uma Pandemia
Introduction/Framework Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis. Despite the available treatment, it’s an important driver of global morbidity and mortality. It reaches mainly the lungs but can reach any organ. The main route of infection is inhalation of aerosolized particles or contaminated micro-droplets. Global efforts for early diagnosis and adequate treatment have made it possible to remove Tuberculosis from the worldwide ten leading causes of death in 2019. The worldwide incidence is around ten million, probably underestimated. Tuberculosis represents an often-overlooked pandemic, which remains an important cause of death from an infectious disease whose, in contrast to other infections, incidence has recently risen as occupational disease. Methodology It’s a narrative review of the national and international guidelines about Tuberculosis in healthcare workers, with an adaptation to the Portuguese reality using estimations from countries with a similar disease incidence. Contents The World Health Organization argues that the benefit of screening and treating Latent Tuberculosis Infection outweighs the individual risks and therefore should be performed whenever possible. Following these guidelines, the Portuguese health council (Direção-Geral da Saúde) determined that health institutions, within the scope of health surveillance of their workers, must adopt procedures that allow for the early detection of Tuberculosis and Latent Tuberculosis Infection. Thus, the Occupational Medicine Services are responsible for assessing and manage the professional exposure to this biological agent. The End TB Strategy program aspires to the worldwide eradication of Tuberculosis by 2035, aiming to reduce Tuberculosis incidence and mortality by 80 and 95%, respectively, as well as universal access to proper treatment. Discussion and Conclusions The authors argue that the institutional contribution with the reinforcement of hospital infection control measures, the implementation of regular occupational Tuberculosis surveillance programs and the containment of the disease, through timely screening after unprotected exposure, are essentials measures for the achievement of the ambitious outlined goals. Regardless of their job model, these programs should be applied to all workers, contributing to the maintenance of their health, the main Occupational Medicine’s goal. Finally, the authors share ten common questions from daily basis clinical practice and present methodological suggestions. KEY-WORDS: Labor Health Surveillance; Healthcare workers; Prevention of Occupational Diseases; Screening; Tuberculosis; Latent Tuberculosis Infection.
- 1 January 2022
- Published by Wolters Kluwer Health in JBJS Case Connector
- Vol. 12 (1)
Multidisciplinary Approach to Multiple Multiresistant Agent Infection of Instrumented Spine Surgery
Case: We report the case of a patient with consecutive infections with several multidrug-resistant agents—including carbapenem-resistant strains of Klebsiella pneumoniae among others—from a surgical wound infection after lumbar spine fusion, only successfully treated after the resort to novel antibiotics (ceftazidime-avibactam) in combination therapy. Conclusions: Multidrug resistance has become a major challenge in today’s medicine. Care should be taken to avoid their emergence, but when present, a multidisciplinary approach is mandatory to ensure clinically up-to-date treatment choices. Multimodal antibiotic schemes tend to show the most promising results, with which successful infection resolution can still be achieved.
- 1 January 2022
- Published by Wolters Kluwer Health in JBJS Case Connector
- Vol. 12 (1)
Multidisciplinary Approach to Multiple Multiresistant Agent Infection of Instrumented Spine Surgery
Case: We report the case of a patient with consecutive infections with several multidrug-resistant agents—including carbapenem-resistant strains of Klebsiella pneumoniae among others—from a surgical wound infection after lumbar spine fusion, only successfully treated after the resort to novel antibiotics (ceftazidime-avibactam) in combination therapy. Conclusions: Multidrug resistance has become a major challenge in today’s medicine. Care should be taken to avoid their emergence, but when present, a multidisciplinary approach is mandatory to ensure clinically up-to-date treatment choices. Multimodal antibiotic schemes tend to show the most promising results, with which successful infection resolution can still be achieved.
- 15 September 2021
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 207 (6) , 1591-1598
SARS-CoV-2 Infection Drives a Glycan Switch of Peripheral T Cells at Diagnosis
COVID-19 is a highly selective disease in which SARS-CoV-2 infection can result in different clinical manifestations ranging from asymptomatic/mild to severe disease that requires hospitalization. In this study, we demonstrated that SARS-CoV-2 infection results in a glycosylation reprogramming of circulating lymphocytes at diagnosis. We identified a specific glycosignature of T cells, defined upon SARS-CoV-2 infection and apparently triggered by a serological factor. This specific glycan switch of T cells is detected at diagnosis being more pronounced in asymptomatic patients. We further demonstrated that asymptomatic patients display an increased expression of a viral-sensing receptor through the upregulation of DC-SIGN in monocytes. We showed that higher levels of DC-SIGN in monocytes at diagnosis correlates with better COVID-19 prognosis. This new evidence pave the way to the identification of a novel glycan-based response in T cells that may confer protection against SARS-CoV-2 infection in asymptomatic patients, highlighting a novel prognostic biomarker and potential therapeutic target. Key Points T cells from COVID-19 patients display less complex N-glycans at diagnosis. IL-2 is a putative driver of glycan switch in COVID-19 patients. DC-SIGN expression in monocytes at diagnosis predicts poor disease course.
- 15 September 2021
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 207 (6) , 1591-1598
SARS-CoV-2 Infection Drives a Glycan Switch of Peripheral T Cells at Diagnosis
COVID-19 is a highly selective disease in which SARS-CoV-2 infection can result in different clinical manifestations ranging from asymptomatic/mild to severe disease that requires hospitalization. In this study, we demonstrated that SARS-CoV-2 infection results in a glycosylation reprogramming of circulating lymphocytes at diagnosis. We identified a specific glycosignature of T cells, defined upon SARS-CoV-2 infection and apparently triggered by a serological factor. This specific glycan switch of T cells is detected at diagnosis being more pronounced in asymptomatic patients. We further demonstrated that asymptomatic patients display an increased expression of a viral-sensing receptor through the upregulation of DC-SIGN in monocytes. We showed that higher levels of DC-SIGN in monocytes at diagnosis correlates with better COVID-19 prognosis. This new evidence pave the way to the identification of a novel glycan-based response in T cells that may confer protection against SARS-CoV-2 infection in asymptomatic patients, highlighting a novel prognostic biomarker and potential therapeutic target. Key Points T cells from COVID-19 patients display less complex N-glycans at diagnosis. IL-2 is a putative driver of glycan switch in COVID-19 patients. DC-SIGN expression in monocytes at diagnosis predicts poor disease course.
- Open Access
- 10 August 2021
- Published by Copernicus GmbH in Journal of Bone and Joint Infection
- Vol. 6 (7) , 305-312
Combined antibiotic therapy spacers either commercial or handmade are superior to monotherapy – a microbiological analysis at the second stage of revision
Background: Antibiotic-loaded spacers are often used during two-stage exchange for periprosthetic joint infections (PJIs) both for its mechanical properties and as a means of local antibiotic delivery. Purpose: The main goal of this study is to compare the efficacy of different options of antibiotic(s) in spacers concerning the rate of positive cultures at the second stage. Patients and Methods: We retrospectively evaluated two-stage exchange procedures for infected hip or knee arthroplasty performed between 2012 and 2018 in which adequate (at least four deep tissue samples) culture results in both stages were available. The type of spacer and antibiotics used, in addition to several other patient, infection and treatment-related variables, were registered and correlated to microbiological findings in the second stage. Results: Fifty-eight cases were included with a 19.0 % (11/58) overall rate of positive cultures during reimplantation. With a mean follow-up of 46 months, failure rate was significantly higher at 63.6 % (7/11) in cases with positive cultures at reimplantation compared to 4.3 % (2/47) for those with negative cultures during reimplantation (p< 0.001). The need for additional surgeries was also significantly higher (odds ratio (OR) 122.67, confidence interval (CI) 95 % 11.30–1331.32, p< 0.001). Multivariable analysis revealed antibiotics in the spacers were the main independent prognostic risk factor associated with positive cultures at the second stage with an advantage for combined antibiotics. Monotherapy is associated with failure with an OR of 16.99. Longer time between surgeries did not have statistical significance (p= 0.05), and previous surgical treatment for PJI, presence of difficult-to-treat microorganism(s), duration of systemic antibiotic therapy or even treatment within a dedicated septic team were not shown to be independent risk factors. Among combined antibiotic spacers, there were no significant differences between the rate of positive cultures during the second stage, comparing commercially available vancomycin/gentamicin spacers to hand-mixed vancomycin/meropenem manufactured spacers (8.3 % [2/24] vs. 15.0 % [3/20], p= 0.68). Conclusions: Results show that combined antibiotic therapy spacers are advantageous when compared to gentamicin monotherapy as they produce significantly lower rates of subsequent positive cultures during the second stage. Hand-mixed high-dose vancomycin/meropenem spacers seem to perform just as well as prefabricated commercially available vancomycin/gentamicin options. Level of Evidence: Therapeutic level III.
- 10 August 2021
- Published by Copernicus GmbH in Journal of Bone and Joint Infection
- Vol. 6 (7) , 305-312
Open AccessCombined antibiotic therapy spacers either commercial or handmade are superior to monotherapy – a microbiological analysis at the second stage of revision
Background: Antibiotic-loaded spacers are often used during two-stage exchange for periprosthetic joint infections (PJIs) both for its mechanical properties and as a means of local antibiotic delivery. Purpose: The main goal of this study is to compare the efficacy of different options of antibiotic(s) in spacers concerning the rate of positive cultures at the second stage. Patients and Methods: We retrospectively evaluated two-stage exchange procedures for infected hip or knee arthroplasty performed between 2012 and 2018 in which adequate (at least four deep tissue samples) culture results in both stages were available. The type of spacer and antibiotics used, in addition to several other patient, infection and treatment-related variables, were registered and correlated to microbiological findings in the second stage. Results: Fifty-eight cases were included with a 19.0 % (11/58) overall rate of positive cultures during reimplantation. With a mean follow-up of 46 months, failure rate was significantly higher at 63.6 % (7/11) in cases with positive cultures at reimplantation compared to 4.3 % (2/47) for those with negative cultures during reimplantation (p< 0.001). The need for additional surgeries was also significantly higher (odds ratio (OR) 122.67, confidence interval (CI) 95 % 11.30–1331.32, p< 0.001). Multivariable analysis revealed antibiotics in the spacers were the main independent prognostic risk factor associated with positive cultures at the second stage with an advantage for combined antibiotics. Monotherapy is associated with failure with an OR of 16.99. Longer time between surgeries did not have statistical significance (p= 0.05), and previous surgical treatment for PJI, presence of difficult-to-treat microorganism(s), duration of systemic antibiotic therapy or even treatment within a dedicated septic team were not shown to be independent risk factors. Among combined antibiotic spacers, there were no significant differences between the rate of positive cultures during the second stage, comparing commercially available vancomycin/gentamicin spacers to hand-mixed vancomycin/meropenem manufactured spacers (8.3 % [2/24] vs. 15.0 % [3/20], p= 0.68). Conclusions: Results show that combined antibiotic therapy spacers are advantageous when compared to gentamicin monotherapy as they produce significantly lower rates of subsequent positive cultures during the second stage. Hand-mixed high-dose vancomycin/meropenem spacers seem to perform just as well as prefabricated commercially available vancomycin/gentamicin options. Level of Evidence: Therapeutic level III.